Advice
Marketing Authorisation withdrawn
The Marketing Authorisation for inotersen (Tegsedi) has been withdrawn.
Medicine details
- Medicine name:
- inotersen (Tegsedi)
- SMC ID:
- SMC2188
- Indication:
For the treatment of stage 1 or stage 2 polyneuropathy in adult patients with hereditary transthyretin amyloidosis (hATTR).
- Pharmaceutical company
- Akcea Therapeutics UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Full
- Status
- Withdrawn
- Date advice published
- 12 August 2019
Additional notes
In February 2026, the Marketing Authorisation for inotersen (Tegsedi) was withdrawn.